Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 3/20 | 0.35 |
| ▸ | RXRG | P48443 | 3/20 | 0.35 |
| ▸ | HNF4A | P41235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865371 | 0.71 | RXRA (0.41) | RXRARXRBRXRG | |
| SCHEMBL5846936 | 0.67 | RXRA (0.50) | RXRAPPARGRXRBRXRG | |
| SCHEMBL11599145 | 0.65 | RXRA (0.42) | RXRARXRBRXRG | |
| SCHEMBL13989982 | 0.61 | CHEK1 (0.41) | RXRARXRBRXRGHNF4A | |
| SCHEMBL5865567 | 0.61 | RXRA (0.49) | RXRARXRBRXRG | |
| SCHEMBL15367660 | 0.59 | RXRA (0.42) | RXRARXRBRXRGHNF4A | |
| SCHEMBL5366510 | 0.59 | RXRA (0.45) | RXRARXRBRXRG | |
| SCHEMBL7760183 | 0.59 | RXRA (0.46) | RXRAPPARGNR1H3RXRBRXRG | |
| SCHEMBL5758511 | 0.59 | ALDH1A1 (0.46) | — | |
| SCHEMBL7622765 | 0.58 | RXRA (0.48) | RXRAPPARGNR1H3RXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071218-B2 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | INCYTE SAN DIEGO INCORPORATED (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1456187-A4 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1456187-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003043998-A1 | N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTEREMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDERS, CANCER, AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144329-A1 | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases | CYP27A1, CYP46A1, PNLIP | RXRA 817/4885PPARG 208/4885NR1H3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.